A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome

Trial Profile

A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Fragile X syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GNX
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Status changed from active, no longer recruiting to completed,according to the results published in Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results assessing safety and efficacy presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Jun 2016 According to a Marinus Pharmaceuticals media release, the company in collaboration with University of California (UC) Davis and Antwerp University Hospital, is continuing to analyze the data and planning to submit the data in its entirety for presentation at the National Fragile X Conference in July.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top